Endoscopic injection of glutaraldehyde cross-linked bovine dermal collagen for correction of vesicoureteral reflux

M. P. Leonard, D. A. Canning, Craig A Peters, J. P. Gearhart, R. D. Jeffs

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

From November 1986 through May 1989, a Eood and Drug Administration approved investigational study was done to assess the safety and efficacy of glutaraldehyde cross-linked bovine dermal collagen in the endoscopic treatment of vesicoureteral refux. Over-all, 57 patients (92 ureters) were treated. The majority of ureters (68.5%) had grade II to III/V vesicoureteral reflux (international classification). One treatment was given in 61.4% of the patients, while 33.3% required 2 and 5.3% required 3 treatments. Nonduplicated/primarily refuxing ureters comprised 68.5% of the total, while 13% were duplex/primarily refluxing and 18.5% were surgical failures. The procedures were performed on an outpatient basis in all but 3 patients. Patients were evaluated by voiding cystourethrogram and renal/bladder sonography before and after treatment at 1 month and 1 year. Cure at 1 month after the last treatment was achieved in 75% of the ureters. Among the ureters cured at 1 month the cure persisted in 79% at 1 year after treatment. Cure at 1 year was achieved in 65% of all ureters evaluated, regardless of the status at 1 month. Procedure-related morbidity was minimal and there were no adverse reactions to the implant substance. Thus, glutaraldehyde cross-linked bovine dermal collagen appears to be safe and effective in the endoscopic treatment of vesicoureteral reflux.

Original languageEnglish (US)
Pages (from-to)115-119
Number of pages5
JournalJournal of Urology
Volume145
Issue number1
StatePublished - Jan 1 1991

Fingerprint

Vesico-Ureteral Reflux
Glutaral
Ureter
Collagen
Skin
Injections
Therapeutics
Ultrasonography
Urinary Bladder
Outpatients
Morbidity
Kidney
Safety
Pharmaceutical Preparations

Keywords

  • vesico-ureteral reflux, collagen, aldehydes

ASJC Scopus subject areas

  • Urology

Cite this

Endoscopic injection of glutaraldehyde cross-linked bovine dermal collagen for correction of vesicoureteral reflux. / Leonard, M. P.; Canning, D. A.; Peters, Craig A; Gearhart, J. P.; Jeffs, R. D.

In: Journal of Urology, Vol. 145, No. 1, 01.01.1991, p. 115-119.

Research output: Contribution to journalArticle

Leonard, M. P. ; Canning, D. A. ; Peters, Craig A ; Gearhart, J. P. ; Jeffs, R. D. / Endoscopic injection of glutaraldehyde cross-linked bovine dermal collagen for correction of vesicoureteral reflux. In: Journal of Urology. 1991 ; Vol. 145, No. 1. pp. 115-119.
@article{1711e5b14581481dbd48fcc8572f57e1,
title = "Endoscopic injection of glutaraldehyde cross-linked bovine dermal collagen for correction of vesicoureteral reflux",
abstract = "From November 1986 through May 1989, a Eood and Drug Administration approved investigational study was done to assess the safety and efficacy of glutaraldehyde cross-linked bovine dermal collagen in the endoscopic treatment of vesicoureteral refux. Over-all, 57 patients (92 ureters) were treated. The majority of ureters (68.5{\%}) had grade II to III/V vesicoureteral reflux (international classification). One treatment was given in 61.4{\%} of the patients, while 33.3{\%} required 2 and 5.3{\%} required 3 treatments. Nonduplicated/primarily refuxing ureters comprised 68.5{\%} of the total, while 13{\%} were duplex/primarily refluxing and 18.5{\%} were surgical failures. The procedures were performed on an outpatient basis in all but 3 patients. Patients were evaluated by voiding cystourethrogram and renal/bladder sonography before and after treatment at 1 month and 1 year. Cure at 1 month after the last treatment was achieved in 75{\%} of the ureters. Among the ureters cured at 1 month the cure persisted in 79{\%} at 1 year after treatment. Cure at 1 year was achieved in 65{\%} of all ureters evaluated, regardless of the status at 1 month. Procedure-related morbidity was minimal and there were no adverse reactions to the implant substance. Thus, glutaraldehyde cross-linked bovine dermal collagen appears to be safe and effective in the endoscopic treatment of vesicoureteral reflux.",
keywords = "vesico-ureteral reflux, collagen, aldehydes",
author = "Leonard, {M. P.} and Canning, {D. A.} and Peters, {Craig A} and Gearhart, {J. P.} and Jeffs, {R. D.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "145",
pages = "115--119",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Endoscopic injection of glutaraldehyde cross-linked bovine dermal collagen for correction of vesicoureteral reflux

AU - Leonard, M. P.

AU - Canning, D. A.

AU - Peters, Craig A

AU - Gearhart, J. P.

AU - Jeffs, R. D.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - From November 1986 through May 1989, a Eood and Drug Administration approved investigational study was done to assess the safety and efficacy of glutaraldehyde cross-linked bovine dermal collagen in the endoscopic treatment of vesicoureteral refux. Over-all, 57 patients (92 ureters) were treated. The majority of ureters (68.5%) had grade II to III/V vesicoureteral reflux (international classification). One treatment was given in 61.4% of the patients, while 33.3% required 2 and 5.3% required 3 treatments. Nonduplicated/primarily refuxing ureters comprised 68.5% of the total, while 13% were duplex/primarily refluxing and 18.5% were surgical failures. The procedures were performed on an outpatient basis in all but 3 patients. Patients were evaluated by voiding cystourethrogram and renal/bladder sonography before and after treatment at 1 month and 1 year. Cure at 1 month after the last treatment was achieved in 75% of the ureters. Among the ureters cured at 1 month the cure persisted in 79% at 1 year after treatment. Cure at 1 year was achieved in 65% of all ureters evaluated, regardless of the status at 1 month. Procedure-related morbidity was minimal and there were no adverse reactions to the implant substance. Thus, glutaraldehyde cross-linked bovine dermal collagen appears to be safe and effective in the endoscopic treatment of vesicoureteral reflux.

AB - From November 1986 through May 1989, a Eood and Drug Administration approved investigational study was done to assess the safety and efficacy of glutaraldehyde cross-linked bovine dermal collagen in the endoscopic treatment of vesicoureteral refux. Over-all, 57 patients (92 ureters) were treated. The majority of ureters (68.5%) had grade II to III/V vesicoureteral reflux (international classification). One treatment was given in 61.4% of the patients, while 33.3% required 2 and 5.3% required 3 treatments. Nonduplicated/primarily refuxing ureters comprised 68.5% of the total, while 13% were duplex/primarily refluxing and 18.5% were surgical failures. The procedures were performed on an outpatient basis in all but 3 patients. Patients were evaluated by voiding cystourethrogram and renal/bladder sonography before and after treatment at 1 month and 1 year. Cure at 1 month after the last treatment was achieved in 75% of the ureters. Among the ureters cured at 1 month the cure persisted in 79% at 1 year after treatment. Cure at 1 year was achieved in 65% of all ureters evaluated, regardless of the status at 1 month. Procedure-related morbidity was minimal and there were no adverse reactions to the implant substance. Thus, glutaraldehyde cross-linked bovine dermal collagen appears to be safe and effective in the endoscopic treatment of vesicoureteral reflux.

KW - vesico-ureteral reflux, collagen, aldehydes

UR - http://www.scopus.com/inward/record.url?scp=0026059598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026059598&partnerID=8YFLogxK

M3 - Article

C2 - 1898520

AN - SCOPUS:0026059598

VL - 145

SP - 115

EP - 119

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -